CAI

CAI

Caris Life Sciences, Inc.
OUTPERFORM

Company Information

SectorHealthcare
IndustryBiotechnology
Market Cap$7.25B
Analysts Rating2.1/5

Recommendation Details

PortfolioSmallcap
DateSep 4, 2026
ForecastQ Daily Probabilities
43.3%
66.1%
26.2%

Smallcap holds up to 12 names drawn from Small caps above $200M at $1+ share price. Small caps at or above their analyst target across a 12-slot book. No maximum hold, each position carries a 25% stop-loss. Benchmark: Russell 2000.

Company Description

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

ForecastQ

Quantitative stock signals powered by custom machine learning models and LLMs.


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.